[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MX2022006596A - Formulaciones inyectables de accion prolongada de sales de pamoato de ketamina. - Google Patents

Formulaciones inyectables de accion prolongada de sales de pamoato de ketamina.

Info

Publication number
MX2022006596A
MX2022006596A MX2022006596A MX2022006596A MX2022006596A MX 2022006596 A MX2022006596 A MX 2022006596A MX 2022006596 A MX2022006596 A MX 2022006596A MX 2022006596 A MX2022006596 A MX 2022006596A MX 2022006596 A MX2022006596 A MX 2022006596A
Authority
MX
Mexico
Prior art keywords
long
injectable formulations
acting injectable
ketamine pamoate
pamoate salts
Prior art date
Application number
MX2022006596A
Other languages
English (en)
Inventor
Tong- Ho Lin
Yung- Shun WEN
Chia- Hsien Chen
Ying- Ting LIU
Rui- Zhi HOU
Zhi- Rong Wu
Original Assignee
Alar Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alar Pharmaceuticals Inc filed Critical Alar Pharmaceuticals Inc
Publication of MX2022006596A publication Critical patent/MX2022006596A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se proporcionan composiciones farmacéuticas de liberación sostenida que incluyen una sal de pamoato de ketamina y un portador farmacéuticamente aceptable de la misma. Las composiciones incluyen suspensión acuosa, solución y sistema de administración de matriz, que pueden proporcionar una liberación sostenida para anestesia, analgesia o tratamiento del sistema nervioso central y enfermedades antiinflamatorias.
MX2022006596A 2019-12-20 2020-12-18 Formulaciones inyectables de accion prolongada de sales de pamoato de ketamina. MX2022006596A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962951061P 2019-12-20 2019-12-20
PCT/CN2020/137496 WO2021121366A1 (en) 2019-12-20 2020-12-18 Long-acting injectable formulations of ketamine pamoate salts

Publications (1)

Publication Number Publication Date
MX2022006596A true MX2022006596A (es) 2022-07-05

Family

ID=76478186

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022006596A MX2022006596A (es) 2019-12-20 2020-12-18 Formulaciones inyectables de accion prolongada de sales de pamoato de ketamina.

Country Status (17)

Country Link
US (1) US20240099994A1 (es)
EP (1) EP4076410A4 (es)
JP (1) JP2023505963A (es)
KR (1) KR20220118427A (es)
CN (1) CN114340603B (es)
AR (1) AR120816A1 (es)
AU (1) AU2020410549A1 (es)
BR (1) BR112022012255A2 (es)
CA (1) CA3152593A1 (es)
CL (1) CL2022001636A1 (es)
CO (1) CO2022003543A2 (es)
IL (1) IL294089A (es)
MX (1) MX2022006596A (es)
PE (1) PE20231942A1 (es)
TW (1) TW202135782A (es)
WO (1) WO2021121366A1 (es)
ZA (1) ZA202203789B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3753557A4 (en) 2018-02-15 2021-12-01 National University Corporation Chiba University PREVENTIVE OR THERAPEUTIC AGENT AND PHARMACEUTICAL COMPOSITION FOR INFLAMMATORY DISEASES OR BONE DISEASES
US11426367B2 (en) 2018-05-04 2022-08-30 Perception Neuroscience, Inc. Methods of treating substance abuse
WO2023178039A1 (en) * 2022-03-14 2023-09-21 Perception Neuroscience, Inc. Pharmaceutical formulations of r-ketamine

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080293695A1 (en) * 2007-05-22 2008-11-27 David William Bristol Salts of physiologically active and psychoactive alkaloids and amines simultaneously exhibiting bioavailability and abuse resistance
US20140275276A1 (en) * 2013-03-15 2014-09-18 Janssen Pharmaceutica Nv Pharmaceutical composition of s-ketamine hydrochloride
EP3533444A4 (en) * 2016-10-27 2020-05-20 National University Corporation Chiba University PHARMACEUTICAL APPLICATIONS OF (N) -NORKETAMINE AND ITS SALTS
CN110325179A (zh) * 2016-12-26 2019-10-11 塞尔利克斯生物私人有限公司 用于治疗慢性疼痛的组合物和方法
US10441544B2 (en) * 2017-10-10 2019-10-15 Douglas Pharmaceuticals, Ltd. Extended release pharmaceutical formulation
WO2019073408A1 (en) * 2017-10-10 2019-04-18 Douglas Pharmaceuticals Ltd. PROLONGED RELEASE PHARMACEUTICAL FORMULATION AND TREATMENT METHODS
WO2019172920A1 (en) * 2018-03-09 2019-09-12 Rk Pharmaceuticals, Llc Injectable composition for controlled-release of active ingredient to manage postoperative pain or neuropathic back pain
EP3761970A4 (en) * 2018-03-26 2022-06-08 Cellix Bio Private Limited COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROLOGICAL DISEASES
WO2020143762A1 (en) * 2019-01-11 2020-07-16 Alar Pharmaceuticals Inc. Ketamine pamoate and use thereof

Also Published As

Publication number Publication date
JP2023505963A (ja) 2023-02-14
CN114340603B (zh) 2024-06-07
TW202135782A (zh) 2021-10-01
CO2022003543A2 (es) 2022-04-19
CA3152593A1 (en) 2021-06-24
KR20220118427A (ko) 2022-08-25
ZA202203789B (en) 2024-09-25
EP4076410A4 (en) 2024-02-07
AR120816A1 (es) 2022-03-23
IL294089A (en) 2022-08-01
AU2020410549A1 (en) 2022-04-14
EP4076410A1 (en) 2022-10-26
US20240099994A1 (en) 2024-03-28
WO2021121366A1 (en) 2021-06-24
CL2022001636A1 (es) 2023-01-27
CN114340603A (zh) 2022-04-12
BR112022012255A2 (pt) 2022-08-30
PE20231942A1 (es) 2023-12-05

Similar Documents

Publication Publication Date Title
ZA202203789B (en) Long-acting injectable formulations of ketamine pamoate salts
UA102517C2 (ru) Замещенные производные морфолина и тиоморфолина, фармацевтическая композиция на их основе и их применение для производства лекарственного средства для лечения расстройства или заболевания центральной нервной системы
PH12019501215A1 (en) Conjugates comprising an glp-1/glucagon dual agonist, a linker and hyaluronic acid
CY1121781T1 (el) Φαρμακοτεχνικες μορφες παρατεταμενης απελευθερωσης της ρασαγιλινης και χρησεις αυτων
MX2022014977A (es) D-metadona y sus derivados para uso en el tratamiento de trastornos del sistema nervioso.
MX2022013865A (es) Materiales sintéticos similares a los lípidos para la administración al cerebro.
MX370141B (es) Profármacos que comprenden un conjugado de ácido hialurónico enlazador agonista dual de glp-1/glucagón.
MX2022004451A (es) Heteroaril-bifenil-amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1.
MX2021012105A (es) Compuestos de pirrol.
MX2022004197A (es) Inhibidores del factor d del complemento para administracion oral.
MX2022006333A (es) Compuesto triheterociclico como inhibidor de jak y uso del mismo.
BR112022009533A2 (pt) Composição farmacêutica para administração oral, e, método para preparar uma composição farmacêutica
CR20190545A (es) Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias
MX2021014458A (es) Compuestos triciclicos.
MX2023012723A (es) Composiciones farmacéuticas y sistemas de administración de medicamentos intravítreos para el tratamiento de enfermedades oculares.
MX2021011795A (es) Composición farmaceutica que comprende esomeprazol 0 sal farmaceuticamente aceptable del mismo y que tiene un perfil de liberación doble.
MX350516B (es) Compuestos de anillo fusionado que contienen nitrogeno como antagonistas crth2.
WO2006106432A3 (en) 4-arylpiperidine derivatives and use thereof for preparing a medicament for the treatment of cns disorders
MX2022008068A (es) Compuesto para el tratamiento y prevención de trastornos del sistema nervioso central.
MX2024000084A (es) Compuesto de tiazololactama dimetil sustituido y uso de este.
UA120764U (uk) Лікарський препарат знеболювальної та спазмолітичної дії "фентаніл"